CLINICAL EVIDENCES ON THE ANTIVIRAL PROPERTIES OF MACROLIDE ANTIBIOTICS IN THE COVID-19 ERA AND BEYOND

Simple item page
dc.contributor.authorPoddighe, Dimitri
dc.contributor.authorAljofan, Mohamad
dc.date.accessioned2021-07-15T04:05:56Z
dc.date.available2021-07-15T04:05:56Z
dc.date.issued2020-09-03
dc.description.abstractMacrolides are a large group of antibiotics characterised by the presence of a macro-lactone ring of variable size. The prototype of macrolide antibiotics, erythromycin was first produced by Streptomyces and associated species more than half a century ago; other related drugs were developed. These drugs have been shown to have several pharmacological properties: in addition to their antibiotic activity, they possess some anti-inflammatory properties and have been also considered against non-bacterial infections. In this review, we analysed the available clinical evidences regarding the potential anti-viral activity of macrolides, by focusing on erythromycin, clarithromycin and azithromycin. Overall, there is no significant evidences so far that macrolides might have a direct benefit on most of viral infections considered in this review (RSV, Influenza, coronaviruses, Ebola and Zika viruses). However, their clinical benefit cannot be ruled out without further and focused clinical studies. Macrolides may improve the clinical course of viral respiratory infections somehow, at least through indirect mechanisms relying on some and variable anti-inflammatory and/or immunomodulatory effects, in addition to their well-known antibacterial activity.en_US
dc.identifier.citationPoddighe, D., & Aljofan, M. (2020). Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond. Antiviral Chemistry and Chemotherapy, 28, 204020662096171. https://doi.org/10.1177/2040206620961712en_US
dc.identifier.issn2040-2066
dc.identifier.urihttps://journals.sagepub.com/doi/10.1177/2040206620961712
dc.identifier.urihttps://doi.org/10.1177/2040206620961712
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/5576
dc.language.isoenen_US
dc.publisherSAGE Publicationsen_US
dc.relation.ispartofseriesAntiviral Chemistry and Chemotherapy;2020, Vol. 0: 1–14
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.subjectType of access: Open Accessen_US
dc.subjectMacrolidesen_US
dc.subjecterythromycinen_US
dc.subjectazithromycinen_US
dc.subjectclarithromycinen_US
dc.subjectrespiratory syncytial virusen_US
dc.subjectinfluenzaen_US
dc.subjectcoronavirusen_US
dc.subjectSARS-CoV-2en_US
dc.titleCLINICAL EVIDENCES ON THE ANTIVIRAL PROPERTIES OF MACROLIDE ANTIBIOTICS IN THE COVID-19 ERA AND BEYONDen_US
dc.typeArticleen_US
workflow.import.sourcescience

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Article 5.pdf
Size:
280.45 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
6.28 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Articles